Bimatoprost as a Treatment for Graves' Orbitopathy

The Role of Bimatoprost in Graves' Periorbitopathy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03708627

Enrollment

Registered

2018-10-17

Start date

2017-11-01

Completion date

2031-07-01

Last updated

2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Ophthalmopathy

Brief summary

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Interventions

DRUGBimatoprost Ophthalmic

Bimatoprost, aka Lumigan, one drop in one eye nightly

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Masking description

Outcomes assessor will evaluate clinical photos. Other measures such as Hertel's exophthalmometry values are objective outcomes which will be made available to the Principal Investigator

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Graves' Ophthalmopathy with Exophthalmos/Proptosis -

Exclusion criteria

Active Graves Disease, Currently pregnant, Taking Steroids \-

Design outcomes

Primary

Measure	Time frame
Reduction in periorbital fat causing improvement in proptosis	1 year

Countries

United States

Contacts

CONTACTEmily Li, MD

eli20@jhmi.edu410-955-1112

PRINCIPAL_INVESTIGATOREmily Li, MD

Johns Hopkins University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026